These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 16822847

  • 1. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, Kates R, Ulm K, Kiechle M, Hoefler H, Ullrich A, Harbeck N.
    J Clin Oncol; 2006 Aug 10; 24(23):3747-55. PubMed ID: 16822847
    [Abstract] [Full Text] [Related]

  • 2. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
    Ye Y, Shi Y, Zhou Y, Du C, Wang C, Zhan H, Zheng B, Cao X, Sun MH, Fu H.
    Ann Surg Oncol; 2010 Dec 10; 17(12):3354-61. PubMed ID: 20844967
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B.
    Cancer Res; 2003 Nov 15; 63(22):8051-6. PubMed ID: 14633738
    [Abstract] [Full Text] [Related]

  • 4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 15; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 7. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
    Marmé F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, Lichter P, Hahn M, Schneeweiss A.
    Ann Oncol; 2010 Aug 04; 21(8):1636-1642. PubMed ID: 20147743
    [Abstract] [Full Text] [Related]

  • 8. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 9. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
    Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, Knyazeva T, Müller S, Gärtner S, Sures I, Wang H, Imyanitov E, Häring HU, Knayzev P, Iacobelli S, Höfler H, Ullrich A.
    Cancer Res; 2002 Feb 01; 62(3):840-7. PubMed ID: 11830541
    [Abstract] [Full Text] [Related]

  • 10. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB.
    Clin Cancer Res; 2006 Aug 01; 12(15):4562-8. PubMed ID: 16899602
    [Abstract] [Full Text] [Related]

  • 11. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
    da Costa Andrade VC, Parise O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B.
    Exp Mol Pathol; 2007 Feb 01; 82(1):53-7. PubMed ID: 17084840
    [Abstract] [Full Text] [Related]

  • 12. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.
    Oncology; 2006 Feb 01; 70(5):366-77. PubMed ID: 17179731
    [Abstract] [Full Text] [Related]

  • 13. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
    Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y.
    Clin Cancer Res; 2005 Oct 15; 11(20):7328-33. PubMed ID: 16243804
    [Abstract] [Full Text] [Related]

  • 14. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
    Wang J, Stockton DW, Ittmann M.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6169-78. PubMed ID: 15448004
    [Abstract] [Full Text] [Related]

  • 15. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
    Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, Santini D, Taffurelli M, Treré D.
    Clin Cancer Res; 2008 Apr 01; 14(7):2199-209. PubMed ID: 18381962
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L, Bendahl PO, Grabau D, Isola J, Lövgren K, Rydén L, Fernö M.
    Breast Cancer Res Treat; 2008 May 01; 109(2):255-62. PubMed ID: 17636398
    [Abstract] [Full Text] [Related]

  • 17. FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition.
    Cho SH, Hong CS, Kim HN, Shin MH, Kim KR, Shim HJ, Hwang JE, Bae WK, Chung IJ.
    Cancer Res Treat; 2017 Jul 01; 49(3):766-777. PubMed ID: 27857023
    [Abstract] [Full Text] [Related]

  • 18. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
    Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I.
    Breast Cancer Res Treat; 2005 Mar 01; 90(2):117-25. PubMed ID: 15803358
    [Abstract] [Full Text] [Related]

  • 19. p53 as a specific prognostic factor in triple-negative breast cancer.
    Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, Kim JS, Jung SS.
    Jpn J Clin Oncol; 2009 Apr 01; 39(4):217-24. PubMed ID: 19304743
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E, Anagnostopoulos K, Tripsianis G, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A.
    Neoplasma; 2008 Apr 01; 55(3):229-38. PubMed ID: 18348656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.